Non Drug Discovery Topics at DDT Boston

August 8, 2008

In addition to the discussion and exhibition of novel drug discovery technologies at the annual Drug Discovery Conference in Boston this week, a number of informal talks with attendees centered around creating drug/device combination products and performing QA/QC of biotherapeutics. Both are activities that take place well beyond drug discovery operations in new drug development.

BCC Research estimates that the total market for drug-device combinations was $5.4 billion in 2004 and is expected to rise at an average annual growth rate of 13.6% to $11.5 billion in 2010. The key category is drug-eluting stent market which could total $8 billion in two years.¹

¹John Sterling, Editor-in-Chief,

read more | digg story

Bookmark and Share